From acid reflux to immune reactions, esophagitis has many causes—learn about its symptoms, types, and the latest treatments ...

Gastric cancer remains a major health challenge worldwide, with nearly 1 million new cases annually contributing to more than ...

"We found that some cancer types responded extremely well to the immunotherapy, including colon and stomach cancer," ...

New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

Gastroenterologists are uniquely positioned to expand their critical role in detecting and treating gastrointestinal diseases ...

Cancer operations that remove whole or parts of an organ can be life-altering. New research suggests that some patients may ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

Learn about a clinical trial that used immunotherapy alone to treat people with several different types of cancer, meaning ...

That unexplained morning bloating or stomach discomfort might have less to do with what you ate and more with how you slept.

esophageal cancer, head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), and cervical cancer patients for treatment with KEYTRUDA. Consequently, PD-L1 IHC 22C3 ...

to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab) 1. PD-L1 IHC 22C3 pharmDx (Code ...